The BPTH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BPTH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The BPTH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
View BPTH Detailed Price Forecast - CNN Money | View BPTH Detailed Summary - Google Finance | ||
View BPTH Detailed Summary - Yahoo! Finance | View BPTH Stock Research & Analysis - Zacks.com |
View BPTH Trends & Analysis - Trade-Ideas | View BPTH Major Holders - Barrons | ||
View BPTH Call Transcripts - NASDAQ | View BPTH Breaking News & Analysis - Seeking Alpha | ||
View BPTH Annual Report - CompanySpotlight.com | View BPTH OTC Short Report - OTCShortReport.com | ||
View BPTH Fundamentals - TradeKing | View BPTH SEC Filings - Bar Chart | ||
View Historical Prices for BPTH - The WSJ | View Performance/Total Return for BPTH - Morningstar | ||
View the Analyst Estimates for BPTH - MarketWatch | View the Earnings History for BPTH - CNBC | ||
View the BPTH Earnings - StockMarketWatch | View BPTH Buy or Sell Recommendations - MacroAxis | ||
View the BPTH Bullish Patterns - American Bulls | View BPTH Short Pain Metrics - ShortPainBot.com |
View BPTH Stock Mentions - StockTwits | View BPTH Stock Mentions - PennyStockTweets | ||
View BPTH Stock Mentions - Twitter | View BPTH Investment Forum News - Investor Hub | ||
View BPTH Stock Mentions - Yahoo! Message Board | View BPTH Stock Mentions - Seeking Alpha |
View Insider Transactions for BPTH - SECform4.com | View Insider Transactions for BPTH - Insider Cow | ||
View BPTH Major Holdings Summary - CNBC | View Insider Disclosure for BPTH - OTC Markets | ||
View Insider Transactions for BPTH - Yahoo! Finance | View Institutional Holdings for BPTH - NASDAQ |
View BPTH Stock Insight & Charts - FinViz.com | View BPTH Investment Charts - StockCharts.com | ||
View BPTH Stock Overview & Charts - BarChart | View BPTH User Generated Charts - Trading View |
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Posted on Friday April 19, 2024
HOUSTON, April 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 375,000 shares of its common stock at a purchase price of $3.225 per share and c
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
Posted on Friday April 19, 2024
Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Posted on Thursday April 18, 2024
HOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 375,000 shares of its common stock at a purchase price per share of $3.225 in a registered d
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
Posted on Thursday April 18, 2024
BP1002 Offers Unique Opportunity for Venetoclax-Resistant AML Patients Utilizing RNAi to Limit AML Cell’s Ability to Produce Cancer Enabling Bcl-2 ProteinHOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced completion of the second dose cohort of the dose escalation portion of its Phase 1/